drugset / Trial / NCT04218123
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Phase 2/3
Completed
40 enrolled
Medical University of South Carolina
American Hearing Research Foundation · collabCures Within Reach · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's disease, but there is evidence that it could be effective in helping with vertigo attacks and other aspects of the disorder.
Timeline
- Start
- 2020-02-05
- Primary completion
- 2023-09-13
- Completion
- 2023-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venlafaxine | Small molecule | 37.5 mg | Oral |